Abstract
The results of the first CMF program (cyclophosphamide, methotrexate, and fluorouracil given for 12 monthly cycles) indicated only a slight benefit for the subgroup of postmenopausal patients with node-positive (N+) breast cancer [2, 9]. Although this finding was not consistently reported in all case series [3], several hypotheses were formulated to interpret the impact of adjuvant results on patients who are postmenopause [e.g., suboptimal drug-dose levels and proportion of estrogen receptor (ER) positive tumors].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bonadonna G, Rossi A, Tancini G, Valagussa P, Veronesi U (1984) CMF adjuvant programs at the Milan Cancer Institute. (this volume)
Bonadonna G, Rossi A, Valagussa P, Banfi A, Veronesi U (1977) The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse, and drug tolerance. Cancer 39: 2904–2915
Bonadonna G, Valagussa P (1983) Chemotherapy of breast cancer: current views and results. Int J Radiat Oncol Biol Phys 9: 279–297
Brambilla C Manuscript in preparation
Brambilla C, De Lena M, Rossi A, Valagussa P, Bonadonna G (1976) Response and survival in advanced breast cancer after two non-cross-resistant combinations. Br Med J 1: 801–804
Clark GM, McGuire WL (1983) Prognostic factors in primary breast cancer. Breast Cancer Res Treat 3: 69–72
Fisher B, Redmond C, Brown A, Wickerham DL, Wolmark N, Allegra J, Escher G, Lippman M, Savlov E, Wittlipp J, Fisher ER, with the contribution of Plotkin D, Bowman D, Wolter J, Bornstein R, Desser R, Frelick R, and other NSABP Investigators (1983) Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1: 227–241
Norton L, Simon R (1977) Tumor size, sensitivity to therapy, and the design of treatment schedule. Cancer Treat Rep 61: 1307–1317
Rossi A, Bonadonna G, Valagussa P, Veronesi U (1981) Multimodal treatment in operable breast cancer: five-year results of the CMF program. Br Med J 282: 1427–1431
Tancini G, Bonadonna G, Valagussa P, Marchini S, Veronesi U (1983) Adjuvant CMF in breast cancer: comparative five-year results of 12 vs 6 cycles. J Clin Oncol 1: 2–10
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Rossi, A., Brambilla, C., Valagussa, P., Bonadonna, G. (1984). Adjuvant Programs for Postmenopausal Women with Node-Positive Breast Cancer:Preliminary Analysis of 5-Year Results. In: Senn, HJ. (eds) Adjuvant Chemotherapy of Breast Cancer. Recent Results in Cancer Research, vol 96. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-82357-2_22
Download citation
DOI: https://doi.org/10.1007/978-3-642-82357-2_22
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-82359-6
Online ISBN: 978-3-642-82357-2
eBook Packages: Springer Book Archive